Add to Favorites
Alternative Name
HRAS, RAS testing
Test Description

Bi-directional sequencing of HRAS exons 2 and 3 which includes sites of common activating mutations in codons 12, 13, 59 and 61.

Clinical Significance

Samples are accepted for somatic and germline HRAS mutation testing. HRAS is highly homologous with KRAS and NRAS; all are members of the most frequently mutated family of oncogenes. HRAS mutations are found in a wide variety of solid tumors, including cancers of the bladder, thyroid, upper digestive tract, and melanoma. Germline HRAS mutations are associated with Costello syndrome, which confers a lifetime risk of approximately 15% for malignant tumors including rhabdomyosarcoma and neuroblastoma in childhood and bladder cancer in adolescence and young adulthood.

Specimen Requirements
  • Peripheral blood: 5 mL in EDTA tube.
  • Bone marrow: 2 mL in EDTA tube.
  • FFPE solid tumor tissue: Paraffin block is preferred. Alternatively, send 1 H&E slide plus 5-10 unstained slides cut at 5 or more microns. Please use positively-charged slides and 10% NBF fixative. Do not use zinc fixatives.
Storage and Transportation

Use cold pack for transport, making sure cold pack is not in direct contact with specimen.

CPT Code(s)*
Turnaround Time

7 days

Level of Service

*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed.